In the current work, the conjugate of curcumin and ferulic acid (compound 1) was developed and then examined utilizing a battery of biochemical assays to assess its pharmacological effectiveness against lung cancer.   The compound 1 was synthesized using steglich esterification in excellent yield and then evaluated for its ability to inhibit the growth of different types of human cancer cells, including cells of the gastric cancer (SGC-7901), breast cancer (MCF7), liver cancer (HepG-2), lung cancer (A549), and human cervical carcinoma (HeLa). It exhibited stronger inhibitory effects on A549 cells compared to the other cell types, indicating its potent anti-lung cancer activity. It induces substantial suppression of many kinases, including EGFR, PI3K, mTOR, and VEGFR2. It exhibited cell cycle suppression of G2/M phase, resulting in a significant rise in apoptosis rate in A549 cells. Compound 1 showed a notable suppression of telomerase activity and a rise in the depolarization of mitochondrial membrane potential in A549 cells. The present study showcased the creation of a curcumin-ferulic acid conjugate (referred to as Compound 1) as a very potent anticancer medication that selectively targets lung cancer cells.